OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?

Where Today's News Shapes Tomorrow